C4X Discovery : C4XD Interim Results Presentation 2023

C4X Discovery

Harnessing the Power of Drug Discovery

Interim Results to 31 January 2023

DISCLAIMER

The contents of this presentation have not been approved by an authorised person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

This presentation has been produced by C4X Discovery Holdings plc (the "Company" or "C4XD") and has not been, and will not be, reviewed or approved by the Financial Conduct Authority of the United Kingdom ("FCA"), London Stock Exchange plc ("LSE"), or any other authority or regulatory body.

This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy any securities in the United States or elsewhere nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment to purchase securities. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended (the

"Securities Act").

This presentation is only addressed to and is only directed at persons in member states of the European Economic Area (the "EEA") who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant member state of the EEA) and any implementing measure in each relevant member state of the EEA ("Qualified Investors"). In the United Kingdom, this presentation is only directed to those persons who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") or (ii) fall within Article 49(2)(a) to (d) of the FPO (all such persons being together referred to as "Relevant Persons"). This presentation must not be acted on or relied upon (a) in the United Kingdom, by persons who are not Relevant Persons, and (b) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this presentation relates is available only to (i) in the United Kingdom, Relevant Persons and (ii) in any member state of the EEA other than the United Kingdom, Qualified Investors, and will be engaged in only with such persons. Solicitations resulting from this presentation will only be responded to if the person concerned is, (i) in the United Kingdom, a Relevant Person, and (ii) in any member state of the EEA other than the United Kingdom, a Qualified Investor.

Neither this presentation nor any part of it, nor the fact of its distribution, shall form the basis of, or be relied on in connection with, any contract or investment decision in relation to the Company or any other entity.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of C4XD or any its respective directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements or for any other communication written or otherwise. No statement in the presentation is intended to be, nor should be construed, as a profit forecast. Neither the Company nor its directors will be obliged to provide the recipient with access to any additional information or to update this presentation with additional information or to correct any inaccuracies which may become apparent. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice. The contents of this presentation have not been independently verified.

The contents of this presentation are being supplied to you solely for your information and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose. If this document has been received in error, it must be returned immediately to the Company. This presentation and the information contained herein regarding the Company are strictly confidential and are being shown to you solely for your information. The information may not be reproduced, distributed to any other person or published, in whole or in part, for any purpose. By receiving this presentation, you become bound by the above-referred confidentiality obligation. Failure to comply with such confidentiality obligation may result in civil, administrative or criminal liabilities.

Certain statements included herein express C4XD's expectations or estimates of future performance and constitute "Forward-looking Statements". Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by C4XD are inherently subject to significant business, economic and competitive uncertainties and contingencies. Such Forward-looking Statements involve known and unknown risks, uncertainties and other factors that may cause the actual financial results, performance or achievements to be materially different from estimated future results, performance or achievements expressed or implied by those Forward-looking Statements and, as such, the Forward-looking Statements are not guarantees of future performance. C4XD expressly disclaims any intention or obligation to update or revise any Forward-looking Statements whether as a result of new information, events or otherwise. No person is authorised to give any information or to make any representation other than as contained in this presentation and, if given or made, such information or representation must not be relied upon as having been authorised by the Company.

The foregoing applies to this presentation, any oral presentation of the information in this document by any person on behalf of the Company and any question-and-answer session that follows any such oral presentation (collectively, the "Information"). By accepting this presentation, you agree to be bound by the foregoing instructions and limitations in respect of the Information.

2 C4XD | Interim Results Presentation

Who We Are

Members of Our Highly Experienced Executive Team and Board

Clive Dix PhD	Brad Hoy	Nick Ray PhD	Bhavna Hunjan
CEO, Board	CFO, Board	CSO	CBO, Board

Xcellsyz

3 C4XD | Interim Results Presentation

Operational Summary

Strong Progress across Key Drug Discovery Programmes

Indivior's Phase 1 multiple ascending dose clinical trial of C4XD's oral Orexin-1 receptor antagonist, C4X_3256 (INDV-2000),

• for substance use disorder is ongoing.
• Sanofi is progressing C4XD's IL-17A inhibitor programme for inflammatory diseases towards the next milestone.
  C4XD signed an exclusive worldwide licensing agreement with AstraZeneca in November 2022, worth up to $402 million, for its
• NRF2 activator programme.
  α4β7 integrin inhibitor programme for inflammatory bowel disease delivered compounds showing improved activity at a lower
• dose compared to example competitor clinical compounds in a pharmacodynamic model after oral dosing.
  MALT-1inhibitor programme for cancer examined a lead compound in a mouse xenograft study that showed equivalent
• efficacy to the Johnson & Johnson clinical compound JnJ-67856633; now identifying candidate shortlist molecules. C4XD programme portfolio expanded in inflammatory diseases and new programmes identified to progress into Lead
• Optimisation and beyond.
  C4XD launched PatientSeek, a Precision Medicine platform for optimised patient selection based on its Taxonomy3® genetic
• analysis technology, following key results from a collaboration with Garvan Institute.

4 C4XD | Interim Results Presentation | Post-period event

A Track Record of Success - Combined Deal Value of >$1 Billion

Validated through Scientific and Commercial Success

2018

2019

2020

2021

2022

2023

Orexin-1

Preclinical payments: $10m	Phase 1 SAD	Phase 1 MAD
($10m received to date)
completion2	initiation3
Total deal value: up to $294m1

IL-17

Preclinical payments: €18m

(€10m received to date)

Total deal value: up to €414m1

NRF2

Preclinical payments: $16m

($2m received to date)

Total deal value: up to $402m1

Out-licensing	Preclinical	Clinical
Deal	Milestone	Trial

5	C4XD | Interim Results Presentation	1.	Total deal value inclusive of preclinical payments
2.	Clinical Trials.gov; NCT04413552 INDV-2000 SAD study completion date 13th April 2021

3. Indivior Q3 2022 Results and R&D Update 10th October 2022; MAD study dosed 14th September 2022 Abbreviations: MAD: Multiple Ascending Dose; SAD: Single Ascending Dose